BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36597972)

  • 1. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients.
    Martín-Varillas JL; Sanchez-Bilbao L; Calvo-Río V; Adán A; Hernanz I; Gallego-Flores A; Beltran-Catalan E; Castro-Oreiro S; Fanlo P; Garcia Martos A; Torre I; Cordero-Coma M; De Dios JR; García-Aparicio Á; Hernández-Garfella M; Sánchez-Andrade A; García-Valle A; Maiz O; Miguélez R; Rodríguez-Montero S; Urruticoechea A; Veroz R; Conesa A; Fernández-Carballido C; Jovaní V; Mondejar JJ; Martínez González O; Moya Alvarado P; Romero-Yuste S; Rubio-Muñoz P; Peña-Sainz-Pardo E; Garijo-Bufort M; Demetrio-Pablo R; Hernández JL; Blanco R
    RMD Open; 2022 Dec; 8(2):. PubMed ID: 36597972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy.
    Prieto-Peña D; Calderón-Goercke M; Adán A; Chamorro-López L; Maíz-Alonso O; De Dios-Jiménez Aberásturi JR; Veroz R; Blanco S; Martín-Santos JM; Navarro F; Gallego A; González-Suárez S; Conesa A; García-Valle A; Cordero-Coma M; Pardiñas-Barón N; Demetrio R; Calvo-Río V; Martínez-Taboada VM; Castañeda S; Hernández JL; González-Gay MA; Blanco R
    Clin Exp Rheumatol; 2021; 39(1):105-114. PubMed ID: 33124565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation.
    Llorenç V; Mesquida M; Sainz de la Maza M; Blanco R; Calvo V; Maíz O; Blanco A; de Dios-Jiménez de Aberásturi JR; Adán A
    Ocul Immunol Inflamm; 2016; 24(2):167-72. PubMed ID: 25325834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and safety of certolizumab pegol in cutaneous symptoms on psoriasis in patients with psoriatic arthritis: A retrospective analysis in real life.
    Dattola A; Mazzeo M; Di Stefano F; Manfreda V; Vollono L; Di Raimondo C; Di Matteo E; Bianchi L
    Dermatol Ther; 2020 May; 33(3):e13409. PubMed ID: 32291887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis.
    Tosi GM; Sota J; Vitale A; Rigante D; Emmi G; Lopalco G; Guerriero S; Orlando I; Iannone F; Frediani B; Angotti R; Messina M; Galeazzi M; Vannozzi L; Cantarini L; Fabiani C
    Clin Exp Rheumatol; 2019; 37(4):680-683. PubMed ID: 30943133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
    Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
    RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis.
    Carubbi F; Fidanza R; Palmieri M; Ventura A; Tambone S; Cipriani P; Giacomelli R; Fargnoli MC
    J Dermatolog Treat; 2020 Nov; 31(7):692-697. PubMed ID: 30963798
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
    Atienza-Mateo B; Calvo-Río V; Beltrán E; Martínez-Costa L; Valls-Pascual E; Hernández-Garfella M; Atanes A; Cordero-Coma M; Miquel Nolla J; Carrasco-Cubero C; Loricera J; González-Vela MC; Vegas-Revenga N; Fernández-Díaz C; Demetrio-Pablo R; Domínguez-Casas LC; Luis Martín-Varillas J; Palmou-Fontana N; Hernández JL; González-Gay MÁ; Blanco R
    Rheumatology (Oxford); 2018 May; 57(5):856-864. PubMed ID: 29471416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients.
    Calvo-Río V; Blanco R; Santos-Gómez M; Rubio-Romero E; Cordero-Coma M; Gallego-Flores A; Veroz R; Torre I; Hernández FF; Atanes A; Loricera J; González-Vela MC; Palmou N; Hernández JL; González-Gay MA
    Semin Arthritis Rheum; 2016 Aug; 46(1):95-101. PubMed ID: 27060872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six months multicentre pilot open label single-arm study to evaluate patient experience, acceptability and satisfaction of switching certolizumab pegol from a prefilled syringe or autoinjection pen to an AVA® e-Device in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis patients.
    Borrás-Blasco J; Vicente-Escrig E; Rodríguez-Lucena FJ; García-Monsalve A; Arroyo-Domingo E; Ferrando-Piqueres R; Casterá E; Navarro-Ruiz A
    J Clin Pharm Ther; 2022 Dec; 47(12):2345-2349. PubMed ID: 36470844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
    Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.
    Deeks ED
    BioDrugs; 2016 Dec; 30(6):607-617. PubMed ID: 27704400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
    Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
    Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study.
    Lopalco G; Emmi G; Gentileschi S; Guerriero S; Vitale A; Silvestri E; Becatti M; Cavallo I; Fabiani C; Frediani B; Iannone F; Cantarini L
    Mod Rheumatol; 2017 Nov; 27(6):1031-1035. PubMed ID: 28712320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Certolizumab pegol for the treatment of psoriasis.
    Campanati A; Benfaremo D; Luchetti MM; Ganzetti G; Gabrielli A; Offidani A
    Expert Opin Biol Ther; 2017 Mar; 17(3):387-394. PubMed ID: 28165828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
    Vavricka SR; Spasojevic M; Rogler G; Schoepfer AM; Seibold F; Borovicka J; Frei P; Zeitz J; Greuter T; Manser C; Scharl M; Misselwitz B; Straumann A; Michetti P; Biedermann L;
    Dig Dis; 2017; 35(5):423-432. PubMed ID: 28595194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature.
    Koda K; Toyoshima M; Nozue T; Suda T
    Intern Med; 2020 Aug; 59(16):2015-2021. PubMed ID: 32389943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW.
    van der Horst-Bruinsma I; van Bentum R; Verbraak FD; Rath T; Rosenbaum JT; Misterska-Skora M; Hoepken B; Irvin-Sellers O; VanLunen B; Bauer L; Rudwaleit M
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.